Undifferentiated iPSC Detection

A key concern in iPSC-based therapeutic applications is the safety of the cell products to be transplanted into patients. Although the in vivo teratoma formation assay is an effective method to directly assess the tumorigenicity of undifferentiated cells, it is also costly and time-consuming. Now, Creative Bioarray presents a quick and cost-effective assay to detect residual undifferentiated iPSCs amongst direct differentiated cells and cells intended to be used in transplantation activities.

We detect the undifferentiated iPS cells by measuring miRNA markers in the cell culture supernatants, which is non-destructive, but more sensitive than other testing methods. This technology could also be used for early cell selection, contributing to the improvement of production efficiency.

Service features:

• More sensitive than the conventional Lin28A method
• Non-destructive
• Measurement of differentiation efficiency
• Evaluation of tumor formation risk

Figure 1. Detection of hiPSCs spiked into human neurons.

Quotation and ordering

We have extensive experience in developing safety analysis of regenerative medicine products. To discuss any of these models further or to discuss the possibility of developing alternative models, please do not hesitate to contact us.

Explore Other Options

• In Vitro DMPK Services
• In Vivo DMPK Services
• Biosample Services
• Cell Services
• Cell-Based Drug Discovery

• iPS Cell Related Products
• iPSC Characterization
• iPSC Differentiation
• iPSC Gene Editing
• iPSC Generation

For research use only. Not for any other purpose.